Test of Novel Drug for Smoking Cessation

Completed · Phase 2 · Has a placebo group

Conditions studied: Smoking Cessation

In brief

The study will assess a novel active drug vs. placebo on ability to reduce smoking and aid cessation during a one-week "practice" quit period for each condition in smokers with a high interest in quitting (i.e. crossover design). Medication effects on reducing withdrawal and cognitive impairment will help assess the mechanism to support quit smoking attempts.

Key facts

Study ID

NCT02217527

Run by

Chengappa, K.N. Roy, MD

People needed

36

Starts

2014-11-01

Expected to finish

2018-01-01

Last updated by the study team

2018-08-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female dependent smokers wanting to quit soon

You may not qualify if…

• Use of non-smoked nicotine products
• Already enrolled in cessation program.
• Recent alcohol or substance dependence (≤ 3 months)
• Women who are pregnant, planning a pregnancy, or lactating; all female participants shall undergo a pregnancy test at screening and will be excluded if positive.
• Serious or unstable medical disorder within the past 3 months
• Epilepsy
• Current diagnosis (within last 6-months) of abnormal cardiac rhythms; unstable cardiovascular disease e.g. stroke, myocardial infarction in the last 6 months
• Evidence impaired liver function test (LFT)
• Evidence of kidney failure
• Any subject with a history of hematological cancers examples: leukemia, lymphoma etc.
• Any clinically significant hematological laboratory abnormality.

Where it is running

• Univ of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.